Welcome to our dedicated page for Medtronic SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medtronic plc filings document material events, capital structure, registered securities, governance matters, and operating and financial disclosures for a medical-device company organized in Ireland. The 8-K record identifies MDT ordinary shares and multiple series of senior notes listed on the New York Stock Exchange, alongside current reports used for company events and financial-result communications.
The filing record also includes exchange and registration status for debt securities, including a Form 25 notice tied to removal from listing and registration of a guarantor class of senior notes. These disclosures frame Medtronic's public-company obligations around equity, debt instruments, material agreements, and regulatory or clinical developments.
Medtronic plc (MDT) reported an insider transaction by its Chief Accounting Officer. On 11/20/2025, the officer disposed of 170 ordinary shares of Medtronic stock at a reported price of $0, which is consistent with a coded gift transaction. After this transaction, the officer beneficially owned 12,357 ordinary shares.
A footnote explains that this ownership total includes 99 shares acquired through dividend reinvestment since the prior report. The filing shows no derivative securities positions for this reporting person.
Medtronic plc executive vice president for Global Operations & Supply Chain reported multiple open-market sales of company ordinary shares. On 11/19/2025, the officer sold several blocks of Medtronic stock at prices around $102 per share, reducing but not eliminating their direct stake. Following these transactions, the officer directly owned 46,016 ordinary shares.
The reported holdings also include 323 shares acquired through dividend reinvestment and 96 shares acquired under Medtronic's Employee Stock Ownership Plan since the prior report, showing ongoing participation in company equity programs alongside the sales.
A Medtronic (MDT) shareholder filed a Form 144 notice to potentially sell 30,000 shares of common stock through Fidelity Brokerage Services on the NYSE, with an approximate aggregate market value of $3,058,452.26. The planned sale date listed is 11/19/2025. The shares come from multiple acquisitions between 2022 and 2025, including employee stock purchase plan buys funded with cash and restricted stock units that vested as compensation. The filing also notes that Medtronic has 1,282,685,882 shares of this class outstanding, giving context for the size of the potential sale relative to the overall share count.
Medtronic plc filed a current report to announce that it released its financial results for the second quarter of its fiscal year 2026. On November 18, 2025, the company issued a press release with these results, which is included as Exhibit 99.1. The report also confirms Medtronic’s status as an Irish public limited company and lists its ordinary shares and various series of senior notes, with maturities ranging from 2027 to 2053, as being listed on the New York Stock Exchange.
Medtronic plc reported that Gregory L. Smith, Executive Vice President, Enterprise Operations, will retire from the company effective December 2, 2025 and plans to join a private equity‑held organization. The company states he will receive retirement treatment for outstanding equity as previously disclosed.
Under those equity terms, unvested stock options will accelerate, while restricted stock units (RSUs) and performance stock units (PSUs) will continue to vest in line with the applicable award agreements filed with the SEC.
Medtronic plc reported the results of its Annual General Meeting held on October 16, 2025. Shareholders approved amendments to the company’s Memorandum and Articles of Association, including changes to Article 177 to allow the Board to capitalize certain non-distributable reserves to create distributable reserves and updates to the advance notice provisions. They also approved a capital reduction to create distributable reserves under Irish law.
All twelve director nominees were elected and shareholders ratified the appointment of PricewaterhouseCoopers LLP as independent auditor for fiscal 2026 and authorized the Board, through the Audit Committee, to set auditor remuneration. Shareholders renewed the Board’s authority to issue shares and to opt out of pre-emption rights under Irish law, and authorized the company and its subsidiaries to make overseas market purchases of ordinary shares. At the record date, 1,282,616,011 ordinary shares were outstanding; 1,109,198,321 were represented at the meeting, constituting a quorum.
Medtronic plc (MDT) appears on a Form 25 notification indicating the class of securities is being removed from listing and/or registration on the New York Stock Exchange LLC. The filing identifies the issuer's principal office at 710 Medtronic Pkwy, Minneapolis, MN and includes the Commission File Number 001-36820. The form cites compliance with 17 CFR 240.12d2-2 provisions for withdrawal or removal. The document provides no explanation of timing, underlying transaction, or impact on shareholders.
Medtronic plc filed an 8-K disclosing a Sixth Supplemental Indenture dated September 29, 2025 among Medtronic, Inc., Medtronic plc and Medtronic Global Holdings S.C.A., with Computershare Trust Company, N.A. as successor trustee and U.S. Bank Europe DAC, UK Branch as paying agent. The filing includes the forms of the 2030 Notes and the 2045 Notes, and attaches legal opinions from U.S., Irish and Luxembourg counsel plus consents from each counsel and an internal opinion by an Assistant Secretary. The submission also references an embedded Cover Page Interactive Data File and is signed by Thierry Pi e9ton, Executive Vice President and Chief Financial Officer.
Medtronic plc filed an 8-K disclosing an Underwriting Agreement dated September 15, 2025 among Medtronic, Inc., Medtronic plc and Medtronic Global Holdings S.C.A., with Deutsche Bank AG, London Branch and Goldman Sachs & Co. LLC named as the representatives of the several underwriters. The filing also notes an embedded Cover Page Interactive Data File with the Inline XBRL document. The filing is signed on September 16, 2025 by Thierry Piéton, Executive Vice President and Chief Financial Officer.
The notice identifies the existence and date of the underwriting arrangement and the lead underwriters but does not disclose transaction size, terms, or intended use of proceeds.
Medtronic plc filed an 8-K disclosing an Underwriting Agreement dated September 15, 2025 among Medtronic, Inc., Medtronic plc and Medtronic Global Holdings S.C.A., with Deutsche Bank AG, London Branch and Goldman Sachs & Co. LLC named as the representatives of the several underwriters. The filing also notes an embedded Cover Page Interactive Data File with the Inline XBRL document. The filing is signed on September 16, 2025 by Thierry Piéton, Executive Vice President and Chief Financial Officer.
The notice identifies the existence and date of the underwriting arrangement and the lead underwriters but does not disclose transaction size, terms, or intended use of proceeds.
Medtronic plc is offering debt securities, including $750,000,000 aggregate principal amount of 4.200% senior notes due October 15, 2045. The prospectus supplement states certain pricing rows showing prices to investors near 99.97% with underwriting discounts of 0.35% and 0.65%, producing proceeds to Medtronic, Inc. around 99.62% and 99.25% respectively. As of July 25, 2025, the company reported approximately $28.6 billion of debt outstanding, including $27.8 billion aggregate principal of senior debt of Medtronic plc, Medtronic Luxco and Medtronic, Inc.
The supplement explains that Medtronic Luxco and Medtronic, Inc. are wholly‑owned indirect subsidiaries of Medtronic plc and that notes issued by Medtronic, Inc. will be fully and unconditionally guaranteed on a joint and several basis by Medtronic plc and Medtronic Luxco. The indenture does not prohibit additional unsecured indebtedness or significant secured indebtedness and certain tax, withholding and investor eligibility provisions are described. Financial statements for Luxco and Medtronic, Inc. are not separately included; Medtronic plc provides alternative summarized disclosure under Regulation S‑X.